WHO Drug Information Vol. 32, No.

4, 2018

ATC/DDD classification
The Anatomical Therapeutic Chemical (ATC) classification system and the
Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and
comparing data on drug use at international, national or local levels. The ATC/
DDD system has become the gold standard for international drug utilization
research. It is maintained by the WHO Collaborating Centre for Drug Statistics
Methodology in Oslo, Norway. Visit www.whocc.no/ for more information.

ATC/DDD classification (temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO International
Working Group for Drug Statistics Methodology in October 2018.

Comments or objections to the decisions from the meeting should be forwarded to the
WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2019. If no
objections are received before this date, the new ATC codes and DDDs will be considered
final and included in the January 2020 version of the ATC/DDD Index.

New ATC 5th level codes

ATC level name/INN ATC code
acalabrutinib L01XE51
amenamevir J05AX26
amlodipine and celecoxib C08CA51
arginine and lysine V03AF11
atorvastatin and omega-3 fatty acids C10BA08
baloxavir marboxil J05AX25
betrixaban B01AF04
brolucizumab S01LA06
cemiplimab L01XC33
crizanlizumab B06AX01
daclatasvir, asunaprevir and beclabuvir J05AP58
darolutamide L02BB06
elagolix H01CC03
elbasvir J05AP10
entinostat L01XX64
Continued

551
 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

New ATC 5th level codes (continued)

ATC level name/INN ATC code

enviomycin J04AB06
esketamine N06AX271)
favipiravir J05AX27
ferrous sodium citrate B03AA12
fimasartan and amlodipine C09DB09
fremanezumab N02CX09
gilteritinib L01XE54
glasdegib L01XX63
glycopyrronium D11AA01
grazoprevir J05AP11
imlifidase L04AA41
inotersen N07XX15
irbesartan, amlodipine and hydrochlorothiazide C09DX07
ivosidenib L01XX62
lamivudine and dolutegravir J05AR25
laninamivir J05AH04
larotrectinib L01XE53
latanoprost and netarsudil S01EE51
latanoprostene bunod S01EE06
luspatercept B03XA06
methionine (11C) V09IX13
mosapride A03FA09
moxidectin P02CX03
opinercept L04AB07
pegvaliase A16AB19
perindopril, bisoprolol and amlodipine C09BX04
plazomicin J01GB14
quizartinib L01XE52
rabeprazole, amoxicillin and clarithromycin A02BD12
Continued

552
WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification

New ATC 5th level codes (continued)

ATC level name/INN ATC code
rabeprazole, amoxicillin and metronidazole A02BD13
ravulizumab L04AA43
rifamycin A07AA13
risankizumab L04AC18
rosuvastatin and fimasartan C10BX16
rosuvastatin and omega-3 fatty acids C10BA07
siponimod L04AA42
solriamfetol N06BA14
sotagliflozin A10BK06
tafenoquine P01BA07
tamsulosin and tadalafil G04CA54
tecovirimat J05AX24
ulinastatin B02AB05
vancomycin S01AA28
vonoprazan, amoxicillin and clarithromycin A02BD14
vonoprazan, amoxicillin and metronidazole A02BD15

1 Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14

553
ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

New ATC level codes (other than 5th levels):

Other hematological agents B06AX

Changes of ATC level names

Previous New ATC code
lactobacillus fermentum lactobacillus G01AX14
microspheres of human perflutren, human albumin microspheres V08DA01
albumin
microspheres of perflutren, phospholipid microspheres V08DA04
phospholipids
perflubutane polymer perflubutane, phospholipid microspheres V08DA06
microspheres
sulfur hexafluoride sulfur hexafluoride, phospholipid V08DA05
microspheres

New DDDs
ATC level name/INN DDD unit Adm.R* ATC code
amenamevir 0.4 g O J05AX26
apalutamide 0.24 g O L02BB05
asunaprevir 0.2 g O J05AP06
brodalumab 15 mg P L04AC12
calcium aminosalicylate 15 g O J04AA03
cerliponase alfa 21 mg P A16AB17
elbasvir 50 mg O J05AP10
enviomycin 1 g P J04AB06
erenumab 2.5 mg P N02CX07
favipiravir 1.6 g O J05AX27
glycerol phenylbutyrate 15 g O A16AX09
grazoprevir 0.1 g O J05AP11
laninamivir 40 mg Inhal.powder J05AH04
levofloxacin 0.24 g Inhal.solution J01MA12
nabilone 3 mg O A04AD11
Continued

554
WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification

New DDDs (continued)

ATC level name/INN DDD unit Adm.R* ATC code
opinercept 7 mg P L04AB07
pentosan polysulfate sodium 0.3 g O G04BX15
peramivir 0.6 g P J05AH03
pridinol 6 mg O M03BX03
semaglutide 0.11 mg P A10BJ06
sodium zirconium cyclosilicate 7.5 g O V03AE10
vidarabine 0.7 g P J05AB03

Changes of DDDs
ATC level name/INN Previous DDD New DDD ATC code

liraglutide 1.2 mg P 1.5 mg P A10BJ02

555
 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

ATC/DDD classification (final)

The following ATC codes and DDDs were agreed at the meeting of the WHO
International Working Group for Drug Statistics Methodology in March 2018.

These are considered as final and will be included in the January 2019 version of the
ATC/DDD Index.

New ATC 5th level codes

ATC level name/INN ATC code
abemaciclib L01XE50
angiotensin II C01CX09
apalutamide L02BB05
avatrombopag B02BX08
candesartan, amlodipine and hydrochlorothiazide C09DX06
cannabidiol N03AX24
cefpodoxime and beta-lactamase inhibitor J01DD64
copanlisib L01XX61
doravirine J05AG06
edaravone N07XX14
fexinidazole P01CA03
fostamatinib B02BX09
gemigliptin and rosuvastatin A10BH52
hydrogen peroxide D11AX25
ibalizumab J05AX23
lamivudine, tenofovir disoproxil and doravirine J05AR24
leuprorelin and bicalutamide L02AE51
metformin, saxagliptin and dapagliflozin A10BD25
omidenepag S01EX06
prasterone G03XX01
talazoparib L01XX60
telotristat A16AX15
trifarotene D10AD06

556
WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification

New ATC level codes (other than 5th levels):

Other sex hormones and modulators of the genital system G03XX

Change of ATC codes:

ATC level name/INN Previous ATC New ATC

dimethyl fumarate N07XX09 L04AX07

Changes of ATC level names

Previous New ATC code
Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09C
plain plain
Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09CA
plain plain
Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09D
combinations combinations
Angiotensin II antagonists and Angiotensin II receptor blockers (ARBs) C09DA
diuretics and diuretics
Angiotensin II antagonists and Angiotensin II receptor blockers (ARBs) C09DB
calcium channel blockers and calcium channel blockers
Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09DX
other combinations other combinations
combinations potassium (different salts in combination) A12BA30

fluoromethylcholine (18F) fluorocholine (18F) V09IX07

557
ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

New DDDs
ATC level name/INN DDD unit Adm.R* ATC code
artemether 0.28 g R P01BE02
artesunate 0.28 g R P01BE03
benralizumab 0.54 mg P R03DX10
chenodeoxycholic acid 1 g O A05AA01
cladribine 0.34 mg O L04AA40
dupilumab 21.4 mg P D11AH05
emicizumab 15 mg P B02BX06
ertugliflozin 10 mg O A10BK04
guselkumab 1.79 mg P L04AC16
letermovir 0.48 g O,P J05AX18
ocrelizumab 3.29 mg P L04AA36
patiromer calcium 8.4 g O V03AE09
rolapitant 0.18 g O A04AD14
telotristat 0.75 g O A16AX15
* Administration Route: O = oral; P= parenteral.

Change of DDD
ATC level name/INN Previous DDD New DDD ATC code

aprepitant 95 mgO 165 mg O A04AD12

aprepitant1 95 mgP 150 mg P A04AD12
temocillin 2 gP 4 g P J01CA17
vasopressin 4 UP 40 U P H01BA01
(argipressin)

1
refers to fosaprepitant

WHO Collaborating Centre for Drug Statistics Methodology

Oslo, November 2018

***

558